Paper42802108PubMed
Methyl 4-O-Demethylbarbatate Destabilises HIF-1α and Enhances Temozolomide Sensitivity in Glioma Cells.
Zhou R and 8 others. Cell Prolif, 2026.
Cite this record
ConductScience Library. Methyl 4-O-Demethylbarbatate Destabilises HIF-1α and Enhances Temozolomide Sensitivity in Glioma Cells. Papers, record 42802108. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42802108
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Methyl 4-O-Demethylbarbatate Destabilises HIF-1α and Enhances Temozolomide Sensitivity in Glioma Cells.
- Journal
- Cell Prolif
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-09-30
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| RS-2024-00413760 | National Research Foundation of Korea (NRF), Korea government (MSIT) | PubMed | ||
| 2120260515565 | BK21 FOUR (Fostering Outstanding Universities for Research) program, the Ministry of Education (MOE, Korea) | PubMed |
Source PubMed
References64
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32478924 | Management of glioblastoma: State of the art and future directions. | CA Cancer J Clin | 2020 | https://conductscience.org/library/papers/32478924 | PubMed |
| 2 | 31105886 | Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer. | Oncotarget | 2019 | https://conductscience.org/library/papers/31105886 | PubMed |
| 3 | 38424190 | Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer. | Exp Mol Med | 2024 | https://conductscience.org/library/papers/38424190 | PubMed |
| 4 | 38665668 | Usnic Acid Targets 14-3-3 Proteins and Suppresses Cancer Progression by Blocking Substrate Interaction. | JACS Au | 2024 | https://conductscience.org/library/papers/38665668 | PubMed |
| 5 | 37596681 | HIF1A-repressed PUS10 regulates NUDC/Cofilin1 dependent renal cell carcinoma migration by promoting the maturation of miR-194-5p. | Cell Biosci | 2023 | https://conductscience.org/library/papers/37596681 | PubMed |
| 6 | 29940786 | Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. | Autophagy | 2018 | https://conductscience.org/library/papers/29940786 | PubMed |
| 7 | 26647409 | HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy. | Technol Cancer Res Treat | 2016 | https://conductscience.org/library/papers/26647409 | PubMed |
| 8 | 37553596 | KITENIN promotes aerobic glycolysis through PKM2 induction by upregulating the c-Myc/hnRNPs axis in colorectal cancer. | Cell Biosci | 2023 | https://conductscience.org/library/papers/37553596 | PubMed |
| 9 | 34677398 | Fungal Depsides-Naturally Inspiring Molecules: Biosynthesis, Structural Characterization, and Biological Activities. | Metabolites | 2021 | https://conductscience.org/library/papers/34677398 | PubMed |
| 10 | 33636580 | Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer. | Phytomedicine | 2021 | https://conductscience.org/library/papers/33636580 | PubMed |
| 11 | 34154413 | Linking a Gene Cluster to Atranorin, a Major Cortical Substance of Lichens, through Genetic Dereplication and Heterologous Expression. | mBio | 2021 | https://conductscience.org/library/papers/34154413 | PubMed |
| 12 | 24333432 | GSK3β negatively regulates HIF1α mRNA stability via nucleolin in the MG63 osteosarcoma cell line. | Biochem Biophys Res Commun | 2014 | https://conductscience.org/library/papers/24333432 | PubMed |
| 13 | 30197329 | The anti-cancer efficacies of diffractaic, lobaric, and usnic acid: In vitro inhibition of glioma. | J Cancer Res Ther | 2018 | https://conductscience.org/library/papers/30197329 | PubMed |
| 14 | 22440258 | The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. | Am J Pathol | 2012 | https://conductscience.org/library/papers/22440258 | PubMed |
| 15 | 18485877 | The epithelial-mesenchymal transition generates cells with properties of stem cells. | Cell | 2008 | https://conductscience.org/library/papers/18485877 | PubMed |
| 16 | 25877753 | Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells. | Tumour Biol | 2015 | https://conductscience.org/library/papers/25877753 | PubMed |
| 17 | 10691731 | Loss of PTEN facilitates HIF-1-mediated gene expression. | Genes Dev | 2000 | https://conductscience.org/library/papers/10691731 | PubMed |
| 18 | 33498369 | Beyond the Warburg Effect: Oxidative and Glycolytic Phenotypes Coexist within the Metabolic Heterogeneity of Glioblastoma. | Cells | 2021 | https://conductscience.org/library/papers/33498369 | PubMed |
| 19 | 26771115 | The Emerging Hallmarks of Cancer Metabolism. | Cell Metab | 2016 | https://conductscience.org/library/papers/26771115 | PubMed |
| 20 | 22122467 | Temozolomide: mechanisms of action, repair and resistance. | Curr Mol Pharmacol | 2012 | https://conductscience.org/library/papers/22122467 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42802108
GET https://conductscience.org/api/papers/v1/42802108/references?page=2